Literature DB >> 18848812

In utero onset of long QT syndrome with atrioventricular block and spontaneous or lidocaine-induced ventricular tachycardia: compound effects of hERG pore region mutation and SCN5A N-terminus variant.

Ming-Tai Lin1, Mei-Hwan Wu, Chien-Chih Chang, Shuenn-Nan Chiu, Olivier Thériault, Hai Huang, Georges Christé, Eckhard Ficker, Mohamed Chahine.   

Abstract

BACKGROUND: Mexiletine may protect patients with long QT syndrome (LQTS) type 3 from arrhythmias. However, we found an unusual in utero presentation of intermittent atrioventricular block and ventricular tachycardia (spontaneous or lidocaine-induced) in a fetus and his sibling with LQTS.
OBJECTIVE: The purpose of this study was to investigate the underlying channelopathy and functional alteration.
METHODS: Mutations were searched in KCNQ1, HERG, KCNE1, KCNE2, and SCN5A genes. In expressed mutants, whole-cell voltage clamp defined the electrophysiologic properties.
RESULTS: Novel missense mutations involving hERG (F627L) at the pore region and SCN5A (R43Q) at the N-terminus were found in the proband and in family members with prolonged QT interval. In oocytes injected with mRNA encoding hERG/ F627L, almost zero K(+) currents were elicited. In coinjected oocytes, the currents were decreased to half. In tsA201 cells transfected with SCN5A/R43Q, although the baseline kinetics of the Na current were similar to wild type, lidocaine caused a unique hyperpolarizing shift of the activation and increased the availability of Na currents at resting voltages. Window currents were enhanced due to a right shift of steady-state inactivation. These electrophysiologic alterations after lidocaine may lead to the development of ventricular tachycardia.
CONCLUSION: We identified a novel hERG/F627L mutation that results in LQTS with fetal onset of atrioventricular block and ventricular tachycardia. A coexisting SCN5A/R43Q variant, although it per se does not prolong repolarization, contributes to the development of ventricular tachyarrhythmias after lidocaine. Patients with such latent lidocaine-induced phenotype who are given lidocaine or mexiletine may be at risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848812     DOI: 10.1016/j.hrthm.2008.08.010

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  7 in total

1.  Dominant-negative effect of SCN5A N-terminal mutations through the interaction of Na(v)1.5 α-subunits.

Authors:  Jérôme Clatot; Azza Ziyadeh-Isleem; Svetlana Maugenre; Isabelle Denjoy; Haiyan Liu; Gilles Dilanian; Stéphane N Hatem; Isabelle Deschênes; Alain Coulombe; Pascale Guicheney; Nathalie Neyroud
Journal:  Cardiovasc Res       Date:  2012-06-27       Impact factor: 10.787

2.  Deep resequencing of the voltage-gated potassium channel subunit KCNE3 gene in chronic tinnitus.

Authors:  Philipp G Sand; Berthold Langguth; Tobias Kleinjung
Journal:  Behav Brain Funct       Date:  2011-09-07       Impact factor: 3.759

3.  Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management.

Authors:  Giovanni Fazio; Federica Vernuccio; Giuseppe Grutta; Giuseppe Lo Re
Journal:  World J Cardiol       Date:  2013-04-26

4.  Life-threatening cardiac arrhythmias due to drug-induced QT prolongation : A retrospective study over 6 years from a medical intensive care unit.

Authors:  G Michels; M Kochanek; R Pfister
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-09-04       Impact factor: 0.840

5.  A rare loss-of-function SCN5A variant is associated with lidocaine-induced ventricular fibrillation.

Authors:  Q Xiong; L Cao; J Hu; A J Marian; K Hong
Journal:  Pharmacogenomics J       Date:  2014-01-21       Impact factor: 3.550

6.  Enhanced impact of SCN5A mutation associated with long QT syndrome in fetal splice isoform.

Authors:  Tiannan Wang; Xander H T Wehrens
Journal:  Heart Rhythm       Date:  2011-11-30       Impact factor: 6.343

7.  Long QT syndrome in South Africa: the results of comprehensive genetic screening.

Authors:  Paula L Hedley; Glenda A Durrheim; Firzana Hendricks; Althea Goosen; Cathrine Jespersgaard; Birgitte Støvring; Tam T Pham; Michael Christiansen; Paul A Brink; Valerie A Corfield
Journal:  Cardiovasc J Afr       Date:  2013-07       Impact factor: 1.167

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.